Can Time to Treatment Be Improved for Lung Cancer Patients by Having Their Case Presented at a Thoracic Multidisciplinary Conference?

October 2016 Vol 7, No 9
Wendy L. Brooks, RN
Lindsey M. Reed, BSN, RN, OCN, ONN-CG
Sarah Cannon

Background: A positive impact is seen in the timeliness to treatment for cancer patients presented at a thoracic multidisciplinary conference. “Timeliness of treatment delivery is one of the key performance indicators of quality care in lung cancer, and there are a number of studies demonstrating that the multidisciplinary model improves time between diagnosis and initiation of treatment. Timely treatment is considered particularly important in lung cancer, as tumors have rapid doubling times, and delays in treatment may result in upstaging and worse outcomes for patients,” and “Health services research that includes studies of patterns of care in lung cancer treatment has identified measures of quality treatment in lung cancer. These include...time between diagnosis and initiation of treatment.”1According to Scher and colleagues, “Studies showed that multidisciplinary care is associated with decreased time between diagnosis and treatment.”2

Purpose: Show that presentation at a thoracic multidisciplinary conference improves timeliness from diagnosis to treatment.

Methods: Sarah Cannon is the oncology service-line for HCA. Sarah Cannon’s proprietary software, iNavigate, is used by oncology nurse navigators to document key data points, including date of diagnosis, date of first treatment, and if patients are presented at a multidisciplinary conference. Midwest division market data were obtained for a 5-month period from January to May 2016 and was reported by month and time to treatment in days. We compared the average time to treatment for our cohort of patients with the total number of lung cancer patients diagnosed in this time frame. The average time to treatment was 20 days.

Results: It was observed over a 5-month period, 19 patients presented at a thoracic multidisciplinary conference were diagnosed with lung cancer and had an overall 35% improvement in timeliness to care from an average of 20 days to 13 days, thus portraying the benefit of improved timeliness to treatment for cancer patients presented at multidisciplinary conference.

Conclusion: Multidisciplinary conference, a requirement for accreditation by the American College of Surgeons Commission on Cancer, has become part of the standard of care for many programs. The improved timeliness to treatment demonstrates the benefit of a multidisciplinary conference to our thoracic program and patients.

Implications/Limitations: Increasing evidence suggests that multidisciplinary conferences improve outcomes. More quality studies are needed to prove that multidisciplinary conferences improve cancer care quality indicators across disease sites and to identify the barriers to successful multidisciplinary care.

References

  1. Denton E, Conron M. Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidiscip Healthc. 2016;9:137-144.
  2. Scher KS, Tisnado DM, Rose DE, et al. Physician and practice characteristics influencing tumor board attendance: results from the provider survey of the Los Angeles Women’s Health Study. J Oncol Pract. 2011;7:103-110.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country